

Mupadolimab

Cat. No.:	HY-P99181
CAS No.:	2451856-97-4
Target:	CD73
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^{POS} B cells ^[1] .		
IC ₅₀ & Target	CD73 ^[1]		
In Vitro	Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	NSG-SGM3 mice, immunized with an emulsion of 50 µg full length spike protein from SARS-CoV-2 and Freund's Incomplete Adjuvant subcutaneously on both the left and right flank (25 µg/side) ^[1]	
	Dosage:	10 mg/kg	
	Administration:	Intraperitoneal injection, daily for 15 days	
	Result:	Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.	

REFERENCES

[1]. Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA